首页 > 最新文献

Current stem cell research & therapy最新文献

英文 中文
Identifying Dental Pulp Stem Cell as A Novel Therapeutic Strategy for Digestive Diseases. 鉴定牙髓干细胞作为一种新的消化系统疾病治疗策略。
Pub Date : 2023-11-24 DOI: 10.2174/011574888X275737231120045815
Xieyin Sun, Zhaoyi Lin, Nuo Xu, Yinqi Chen, Saiyan Bian, Wenjie Zheng

Mesenchymal stem cells (MSCs) have been identified as potential therapeutics for various diseases. In contrast to other sources of MSCs, dental stem cells (DSCs) have received increased attention due to their high activity and easy accessibility. Among them, dental pulp stem cells (DPSCs) exhibit superior self-renewal, multipotency, immunomodulatory, and regenerative capacities. Following their inspiring performance in animal models and clinical trials, DPSCs show pharmacological potential in regenerative medicine. In this review, we have generalized the sources, heterogeneity, and biological characteristics of DPSCs, as well as compared them with other types of dental stem cells. In addition, we summarized the application of DPSCs in digestive diseases (such as liver, esophageal, and intestinal diseases), highlighting their regenerative and pharmacological potential based on the existing preclinical and clinical evidence. Specifically, DPSCs can be> home to injured or inflamed tissues and exert repair and regeneration functions by> facilitating immune regulation, anti-inflammation, and directional differentiation. Although DPSCs have a rosy prospect, future studies should handle the underlying drawbacks and pave the way for the identification of DPSCs as novel regenerative medicine.

间充质干细胞(MSCs)已被确定为多种疾病的潜在治疗药物。与其他来源的间充质干细胞相比,牙干细胞(DSCs)因其高活性和易于获取而受到越来越多的关注。其中,牙髓干细胞(DPSCs)具有较强的自我更新、多能性、免疫调节和再生能力。继在动物模型和临床试验中令人鼓舞的表现后,DPSCs在再生医学中显示出药理学潜力。本文综述了DPSCs的来源、异质性和生物学特性,并将其与其他类型的牙科干细胞进行了比较。此外,我们总结了DPSCs在消化系统疾病(如肝脏、食管和肠道疾病)中的应用,并在现有临床前和临床证据的基础上强调了其再生和药理潜力。具体来说,DPSCs可以通过促进免疫调节、抗炎症和定向分化,将损伤或炎症组织安置在家中,发挥修复和再生功能。尽管DPSCs具有美好的前景,但未来的研究应解决其潜在的缺陷,为DPSCs作为新型再生医学的鉴定铺平道路。
{"title":"Identifying Dental Pulp Stem Cell as A Novel Therapeutic Strategy for Digestive Diseases.","authors":"Xieyin Sun, Zhaoyi Lin, Nuo Xu, Yinqi Chen, Saiyan Bian, Wenjie Zheng","doi":"10.2174/011574888X275737231120045815","DOIUrl":"https://doi.org/10.2174/011574888X275737231120045815","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) have been identified as potential therapeutics for various diseases. In contrast to other sources of MSCs, dental stem cells (DSCs) have received increased attention due to their high activity and easy accessibility. Among them, dental pulp stem cells (DPSCs) exhibit superior self-renewal, multipotency, immunomodulatory, and regenerative capacities. Following their inspiring performance in animal models and clinical trials, DPSCs show pharmacological potential in regenerative medicine. In this review, we have generalized the sources, heterogeneity, and biological characteristics of DPSCs, as well as compared them with other types of dental stem cells. In addition, we summarized the application of DPSCs in digestive diseases (such as liver, esophageal, and intestinal diseases), highlighting their regenerative and pharmacological potential based on the existing preclinical and clinical evidence. Specifically, DPSCs can be> home to injured or inflamed tissues and exert repair and regeneration functions by> facilitating immune regulation, anti-inflammation, and directional differentiation. Although DPSCs have a rosy prospect, future studies should handle the underlying drawbacks and pave the way for the identification of DPSCs as novel regenerative medicine.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgements to Reviewers 审稿人致谢
Pub Date : 2023-11-01 DOI: 10.2174/1574888x1808230515142018
{"title":"Acknowledgements to Reviewers","authors":"","doi":"10.2174/1574888x1808230515142018","DOIUrl":"https://doi.org/10.2174/1574888x1808230515142018","url":null,"abstract":"","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136102773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities. 深入了解用于疾病建模的肝脏微组织的生物制造:挑战和机遇。
Pub Date : 2023-10-13 DOI: 10.2174/011574888X257744231009071810
Hengameh Dortaj, Negar Azarpira, Sara Pakbaz

In the last decade, liver diseases with high mortality rates have become one of the most important health problems in the world. Organ transplantation is currently considered the most effective treatment for compensatory liver failure. An increasing number of patients and shortage of donors has led to the attention of reconstructive medicine methods researchers. The biggest challenge in the development of drugs effective in chronic liver disease is the lack of a suitable preclinical model that can mimic the microenvironment of liver problems. Organoid technology is a rapidly evolving field that enables researchers to reconstruct, evaluate, and manipulate intricate biological processes in vitro. These systems provide a biomimetic model for studying the intercellular interactions necessary for proper organ function and architecture in vivo. Liver organoids, formed by the self-assembly of hepatocytes, are microtissues and can exhibit specific liver characteristics for a long time in vitro. Hepatic organoids are identified as an impressive tool for evaluating potential cures and modeling liver diseases. Modeling various liver diseases, including tumors, fibrosis, non-alcoholic fatty liver, etc., allows the study of the effects of various drugs on these diseases in personalized medicine. Here, we summarize the literature relating to the hepatic stem cell microenvironment and the formation of liver Organoids.

在过去的十年里,高死亡率的肝病已成为世界上最重要的健康问题之一。器官移植目前被认为是治疗代偿性肝衰竭最有效的方法。越来越多的患者和捐赠者的短缺引起了重建医学方法研究人员的注意。开发对慢性肝病有效的药物的最大挑战是缺乏一个合适的临床前模型来模拟肝脏问题的微环境。类器官技术是一个快速发展的领域,使研究人员能够在体外重建、评估和操纵复杂的生物过程。这些系统为研究体内适当器官功能和结构所需的细胞间相互作用提供了仿生模型。肝类器官是由肝细胞自组装形成的,是微小的问题,可以在体外长时间表现出特定的肝脏特征。肝脏类器官被认为是评估潜在治疗方法和肝脏疾病建模的一个令人印象深刻的工具。对各种肝脏疾病进行建模,包括肿瘤、纤维化、非酒精性脂肪肝等,可以在个性化医学中研究各种药物对这些疾病的影响。在此,我们总结了有关肝干细胞微环境和肝类器官形成的文献。
{"title":"Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities.","authors":"Hengameh Dortaj,&nbsp;Negar Azarpira,&nbsp;Sara Pakbaz","doi":"10.2174/011574888X257744231009071810","DOIUrl":"https://doi.org/10.2174/011574888X257744231009071810","url":null,"abstract":"<p><p>In the last decade, liver diseases with high mortality rates have become one of the most important health problems in the world. Organ transplantation is currently considered the most effective treatment for compensatory liver failure. An increasing number of patients and shortage of donors has led to the attention of reconstructive medicine methods researchers. The biggest challenge in the development of drugs effective in chronic liver disease is the lack of a suitable preclinical model that can mimic the microenvironment of liver problems. Organoid technology is a rapidly evolving field that enables researchers to reconstruct, evaluate, and manipulate intricate biological processes in vitro. These systems provide a biomimetic model for studying the intercellular interactions necessary for proper organ function and architecture in vivo. Liver organoids, formed by the self-assembly of hepatocytes, are microtissues and can exhibit specific liver characteristics for a long time in vitro. Hepatic organoids are identified as an impressive tool for evaluating potential cures and modeling liver diseases. Modeling various liver diseases, including tumors, fibrosis, non-alcoholic fatty liver, etc., allows the study of the effects of various drugs on these diseases in personalized medicine. Here, we summarize the literature relating to the hepatic stem cell microenvironment and the formation of liver Organoids.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer Stem Cells and Treatment of Cancer: An Update and Future Perspectives. 癌症干细胞与癌症治疗:最新进展和未来展望。
Pub Date : 2023-10-05 DOI: 10.2174/011574888X247548230921063514
Mudassir Khan, Mashal Naeem, Sana Aftab Chaudary, Affan Ahmed, Aftab Ahmed
Cancer stem cells (CSCs) play an essential role in tumour progression and metastasis. These cells have the unique ability to self-renew and differentiate into specific tissue cell types. Their capacity for self-renewal enables CSCs to persist over time, thereby contributing to cancer relapse and therapy resistance. Therefore, targeting CSCs has emerged as a promising cancer treatment strategy. CSCs exhibit differentiation, self-renewal, and plasticity, and they contribute to multiple aspects of malignant tumours, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. While conventional treatments predominantly target cancer cells that are not CSCs, CSCs frequently survive, resulting in tumour recurrence and relapse. This article concentrates on the development of novel therapeutic strategies that combine conventional treatments with CSC inhibitors to eradicate cancer cells and CSCs, thereby treating cancer and preventing its recurrence. However, the diversity of CSCs poses a significant obstacle to the development of CSC-targeted therapies, necessitating extensive research for a better understanding and exploration of therapeutic approaches. Future development of CSC-targeted therapies will rely heavily on overcoming this obstacle.
癌症干细胞(CSCs)在肿瘤进展和转移中起着重要作用。这些细胞具有独特的自我更新和分化为特定组织细胞类型的能力。它们的自我更新能力使CSC能够持续一段时间,从而导致癌症复发和治疗耐药性。因此,靶向CSCs已成为一种很有前途的癌症治疗策略。CSC表现出分化、自我更新和可塑性,它们与恶性肿瘤的多个方面有关,如复发、转移、异质性、多药耐药性和辐射耐药性。虽然传统治疗主要针对非CSC的癌症细胞,但CSC经常存活,导致肿瘤复发和复发。本文着重于开发新的治疗策略,将常规治疗与CSC抑制剂相结合,以根除癌症细胞和CSC,从而治疗癌症并预防其复发。然而,CSC的多样性对CSC靶向疗法的发展构成了重大障碍,需要进行广泛的研究,以更好地理解和探索治疗方法。CSC靶向治疗的未来发展将在很大程度上依赖于克服这一障碍。
{"title":"Cancer Stem Cells and Treatment of Cancer: An Update and Future Perspectives.","authors":"Mudassir Khan,&nbsp;Mashal Naeem,&nbsp;Sana Aftab Chaudary,&nbsp;Affan Ahmed,&nbsp;Aftab Ahmed","doi":"10.2174/011574888X247548230921063514","DOIUrl":"https://doi.org/10.2174/011574888X247548230921063514","url":null,"abstract":"Cancer stem cells (CSCs) play an essential role in tumour progression and metastasis. These cells have the unique ability to self-renew and differentiate into specific tissue cell types. Their capacity for self-renewal enables CSCs to persist over time, thereby contributing to cancer relapse and therapy resistance. Therefore, targeting CSCs has emerged as a promising cancer treatment strategy. CSCs exhibit differentiation, self-renewal, and plasticity, and they contribute to multiple aspects of malignant tumours, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. While conventional treatments predominantly target cancer cells that are not CSCs, CSCs frequently survive, resulting in tumour recurrence and relapse. This article concentrates on the development of novel therapeutic strategies that combine conventional treatments with CSC inhibitors to eradicate cancer cells and CSCs, thereby treating cancer and preventing its recurrence. However, the diversity of CSCs poses a significant obstacle to the development of CSC-targeted therapies, necessitating extensive research for a better understanding and exploration of therapeutic approaches. Future development of CSC-targeted therapies will rely heavily on overcoming this obstacle.","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenchymal Stem Cell-conditioned Medium Protecting Renal Tubular Epithelial Cells by Inhibiting Hypoxia-inducible Factor-1α and Nuclear Receptor Coactivator-1. 间充质干细胞条件培养基通过抑制缺氧诱导因子-1α和核受体辅活化因子-1保护肾小管上皮细胞。
Pub Date : 2023-10-04 DOI: 10.2174/011574888X247652230928064627
Chunling Liao, Wenjuan Weng, Yiping Liu, Yongda Lin, Jiali Wang, Tianbiao Zhou

Background: Acute kidney injury (AKI) is characterized by inflammatory infiltration and damage and death of renal tubular epithelial cells (RTECs), in which hypoxia plays an important role. Deferoxamine (DFO) is a well-accepted chemical hypoxia-mimetic agent. Mesenchymal stem cell-conditioned medium (MSC-CM) can reduce local inflammation and repair tissue. In this study, we explored the effect and molecular mechanism of MSC-CM-mediated protection of RTECs under DFO-induced hypoxia.

Methods: Rat renal proximal tubule NRK-52E cells were treated with different concentrations of DFO for 24 hours, followed by evaluation of RTEC injury, using a Cell Counting Kit-8 (CCK-8) to detect cell viability and western blotting to evaluate the expression of transforming growth factor- beta 1 (TGF-β1), α-smooth muscle actin (α-SMA), and hypoxia-inducible factor-1 alpha (HIF-1α) in NRK-52E cells. Then, three groups of NRK-52E cells were used in experiments, including normal control (NC), 25 μM DFO, and 25 μM DFO + MSC-CM. MSC-CM was obtained from the human umbilical cord. MSC-CM was used to culture cells for 12 hours before DFO treatment, then fresh MSC-CM and 25 μM DFO were added, and cells were cultured for another 24 hours before analysis.

Results: Western blotting and cellular immunofluorescence staining showed culture of NRK-52E cells in 25 μM DFO for 24 hours induced HIF-1α and nuclear receptor coactivator-1 (NCoA-1), simulating hypoxia. MSC-CM could inhibit the DFO-induced up-regulation of α-SMA, TGF-β1, HIF-1α and NCoA-1.

Conclusion: Our results suggest that MSC-CM has a protective effect on RTECs by down-regulating HIF-1α and NCoA-1, which may be the harmful factors in renal injury.

背景:急性肾损伤(AKI)以炎症浸润、肾小管上皮细胞损伤和死亡为特征,缺氧在其中起着重要作用。去甲氧胺(DFO)是一种公认的化学模拟缺氧剂。间充质干细胞条件培养基(MSC-CM)可以减少局部炎症,修复组织。在本研究中,我们探讨了MSC-CM介导的RTEC在DFO诱导的缺氧下的保护作用及其分子机制。方法:用不同浓度的DFO处理大鼠肾近端小管NRK-52E细胞24小时,然后评估RTEC损伤,使用细胞计数试剂盒-8(CCK-8)检测细胞活力,并用蛋白质印迹法评估转化生长因子-β1(TGF-β1)、α-平滑肌肌动蛋白(α-SMA),和缺氧诱导因子-1α(HIF-1α)在NRK-52E细胞中的表达。然后,使用三组NRK-52E细胞进行实验,包括正常对照(NC)、25μM DFO和25μM DFO+MSC-CM。MSC-CM是从人脐带中获得的。在DFO处理前,使用MSC-CM培养细胞12小时,然后加入新鲜MSC-CM和25μM DFO,并在分析前再培养细胞24小时。结果:Western印迹和细胞免疫荧光染色显示,NRK-52E细胞在25μM DFO中培养24小时,诱导HIF-1α和核受体共激活因子-1(NCoA-1),模拟缺氧。MSC-CM可抑制DFO诱导的α-SMA、TGF-β1、HIF-1α和NCoA-1的上调。
{"title":"Mesenchymal Stem Cell-conditioned Medium Protecting Renal Tubular Epithelial Cells by Inhibiting Hypoxia-inducible Factor-1α and Nuclear Receptor Coactivator-1.","authors":"Chunling Liao,&nbsp;Wenjuan Weng,&nbsp;Yiping Liu,&nbsp;Yongda Lin,&nbsp;Jiali Wang,&nbsp;Tianbiao Zhou","doi":"10.2174/011574888X247652230928064627","DOIUrl":"https://doi.org/10.2174/011574888X247652230928064627","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is characterized by inflammatory infiltration and damage and death of renal tubular epithelial cells (RTECs), in which hypoxia plays an important role. Deferoxamine (DFO) is a well-accepted chemical hypoxia-mimetic agent. Mesenchymal stem cell-conditioned medium (MSC-CM) can reduce local inflammation and repair tissue. In this study, we explored the effect and molecular mechanism of MSC-CM-mediated protection of RTECs under DFO-induced hypoxia.</p><p><strong>Methods: </strong>Rat renal proximal tubule NRK-52E cells were treated with different concentrations of DFO for 24 hours, followed by evaluation of RTEC injury, using a Cell Counting Kit-8 (CCK-8) to detect cell viability and western blotting to evaluate the expression of transforming growth factor- beta 1 (TGF-β1), α-smooth muscle actin (α-SMA), and hypoxia-inducible factor-1 alpha (HIF-1α) in NRK-52E cells. Then, three groups of NRK-52E cells were used in experiments, including normal control (NC), 25 μM DFO, and 25 μM DFO + MSC-CM. MSC-CM was obtained from the human umbilical cord. MSC-CM was used to culture cells for 12 hours before DFO treatment, then fresh MSC-CM and 25 μM DFO were added, and cells were cultured for another 24 hours before analysis.</p><p><strong>Results: </strong>Western blotting and cellular immunofluorescence staining showed culture of NRK-52E cells in 25 μM DFO for 24 hours induced HIF-1α and nuclear receptor coactivator-1 (NCoA-1), simulating hypoxia. MSC-CM could inhibit the DFO-induced up-regulation of α-SMA, TGF-β1, HIF-1α and NCoA-1.</p><p><strong>Conclusion: </strong>Our results suggest that MSC-CM has a protective effect on RTECs by down-regulating HIF-1α and NCoA-1, which may be the harmful factors in renal injury.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic and Safety Promise of Mesenchymal Stem Cells for Liver Failure: from Preclinical Experiment to Clinical Application. 间充质干细胞治疗肝衰竭的疗效和安全性前景:从临床前实验到临床应用。
Pub Date : 2023-10-03 DOI: 10.2174/011574888X260690230921174343
Qiong Xie, Jundong Gu
Liver failure (LF) is serious liver damage caused by multiple factors, resulting in severe impairment or decompensation of liver synthesis, detoxification, metabolism, and biotransformation. The general prognosis of LF is poor with high mortality in non-transplant patients. The clinical treatments for LF are mainly internal medicine comprehensive care, an artificial liver support system, and liver transplantation. However, none of the above treatment strategies can solve the problems of all liver failure patients and has its own limitations. Mesenchymal stem cells (MSCs) are a kind of stem cells with multidirectional differentiation potential and paracrine function, which play an important role in immune regulation and tissue regeneration. In recent years, MSCs have shown multiple advantages in the treatment of LF in pre-clinical experiments and clinical trials. In this work, we reviewed the biological characteristics of MSCs, the possible molecular mechanisms of MSCs in the treatment of liver failure, animal experiments, and clinical application, and also discussed the existing problems of MSCs in the treatment of liver failure.
肝衰竭(LF)是由多种因素引起的严重肝损伤,导致肝脏合成、解毒、代谢和生物转化严重受损或失代偿。LF的一般预后较差,非移植患者的死亡率较高。LF的临床治疗主要是内科综合护理、人工肝支持系统和肝移植。然而,上述治疗策略都不能解决所有肝衰竭患者的问题,并且有其自身的局限性。间充质干细胞是一种具有多向分化潜能和旁分泌功能的干细胞,在免疫调节和组织再生中发挥着重要作用。近年来,MSCs在临床前实验和临床试验中显示出治疗LF的多种优势。本文综述了骨髓间充质干细胞的生物学特性、其治疗肝功能衰竭的可能分子机制、动物实验和临床应用,并讨论了骨髓间质干细胞在肝功能衰竭治疗中存在的问题。
{"title":"Therapeutic and Safety Promise of Mesenchymal Stem Cells for Liver Failure: from Preclinical Experiment to Clinical Application.","authors":"Qiong Xie,&nbsp;Jundong Gu","doi":"10.2174/011574888X260690230921174343","DOIUrl":"https://doi.org/10.2174/011574888X260690230921174343","url":null,"abstract":"Liver failure (LF) is serious liver damage caused by multiple factors, resulting in severe impairment or decompensation of liver synthesis, detoxification, metabolism, and biotransformation. The general prognosis of LF is poor with high mortality in non-transplant patients. The clinical treatments for LF are mainly internal medicine comprehensive care, an artificial liver support system, and liver transplantation. However, none of the above treatment strategies can solve the problems of all liver failure patients and has its own limitations. Mesenchymal stem cells (MSCs) are a kind of stem cells with multidirectional differentiation potential and paracrine function, which play an important role in immune regulation and tissue regeneration. In recent years, MSCs have shown multiple advantages in the treatment of LF in pre-clinical experiments and clinical trials. In this work, we reviewed the biological characteristics of MSCs, the possible molecular mechanisms of MSCs in the treatment of liver failure, animal experiments, and clinical application, and also discussed the existing problems of MSCs in the treatment of liver failure.","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetics, Bone Remodeling and Osteoporosis. 表观遗传学、骨重塑和骨质疏松症。
Pub Date : 2016-12-21
Shaoqing Yang, Xiaohong Duan

Epigenetic regulation, including modifications of DNA, histone proteins and non-coding RNAs, play an important role in the regulation of gene expression and keep the heritable traits of progeny cells without changing DNA sequence. Recent years, epigenetic regulation of bone homeostasis are widely investigated and considered as a vital factor during the differentiation and function of osteoblasts, osteoclasts and osteocytes. Osteoporosis is a common degenerative bone disease which is characterized with decreased bone strength and increased risk of fracture. It has been testified that the abnormal bone metabolism homeostasis, especially in osteoclast function, take a fundamental role in osteoporosis pathogenesis. The reports between osteoporosis and epigenetic regulations are also increased gradually in recent years. In this review, we summarize the current developments of epigenetic regulation mechanism in bone development and remodeling, and emphasize the epigenetic features of osteoporosis and the potent therapy application of epigenetic drugs for osteoporosis.

表观遗传调控包括 DNA、组蛋白和非编码 RNA 的修饰,在调控基因表达和保持后代细胞遗传性状方面发挥着重要作用,而无需改变 DNA 序列。近年来,骨稳态的表观遗传调控被广泛研究,并被认为是成骨细胞、破骨细胞和骨细胞分化和功能发挥过程中的重要因素。骨质疏松症是一种常见的退行性骨病,其特点是骨强度降低和骨折风险增加。有研究证实,骨代谢平衡异常,尤其是破骨细胞功能异常,在骨质疏松症的发病机制中起着根本性的作用。近年来,关于骨质疏松症与表观遗传调控之间关系的报道也逐渐增多。在这篇综述中,我们总结了骨发育和重塑过程中表观遗传调控机制的最新进展,并强调了骨质疏松症的表观遗传学特征以及表观遗传药物在骨质疏松症中的有效治疗应用。
{"title":"Epigenetics, Bone Remodeling and Osteoporosis.","authors":"Shaoqing Yang, Xiaohong Duan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epigenetic regulation, including modifications of DNA, histone proteins and non-coding RNAs, play an important role in the regulation of gene expression and keep the heritable traits of progeny cells without changing DNA sequence. Recent years, epigenetic regulation of bone homeostasis are widely investigated and considered as a vital factor during the differentiation and function of osteoblasts, osteoclasts and osteocytes. Osteoporosis is a common degenerative bone disease which is characterized with decreased bone strength and increased risk of fracture. It has been testified that the abnormal bone metabolism homeostasis, especially in osteoclast function, take a fundamental role in osteoporosis pathogenesis. The reports between osteoporosis and epigenetic regulations are also increased gradually in recent years. In this review, we summarize the current developments of epigenetic regulation mechanism in bone development and remodeling, and emphasize the epigenetic features of osteoporosis and the potent therapy application of epigenetic drugs for osteoporosis.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current stem cell research & therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1